Maintenance therapy with Ninlaro (ixazomib) and Revlimid (lenalidomide) may improve progression-free survival compared with Revlimid alone in patients with myeloma who recently underwent a stem cell transplant, according to recent study results.
In addition, this combination maintenance therapy was safe and tolerable in patients, according to the study published in Clinical Cancer Research.
This phase 2 study started in 2012, when Revlimid maintenance was recently approved by the Food and Drug Administration for patients with myeloma. This approval was based on studies published a year or two before, which demonstrated that Revlimid maintenance after stem cell transplant improved progression-free survival (the length of time after stem cell transplant that a patient lives with cancer without disease progression) by at least a year and a half. Other studies showed that patients also had improvements in overall survival (the time a patient with cancer is still alive) with Revlimid maintenance compared with placebo.
Our goal was how can we make that even better, so combination maintenance, said Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center in Houston, in an interview with CURE. This is one of the first studies that looked at that combination.
Maintenance Therapy After Stem Cell Transplant
In this study, researchers assessed the effects of maintenance therapy with Ninlaro and Revlimid in 64 patients (65.6% men; 64.1% aged 60 years and older) with newly diagnosed multiple myeloma who underwent autologous stem cell transplant. Of note, maintenance therapy was initiated within 60 to 180 days after stem cell infusion.
(Ninlaro) is (an) oral (drug), which is really important when were doing maintenance because these patients have just gone through a stem cell transplant, they just had chemo right before that, Patel said. Their myelomas usually under control, and now were just trying to keep it controlled for longer before we have to treat it again. (An) oral (drug) makes a huge difference.
Researchers monitored several factors throughout the study including progression-free survival, overall survival and duration of response (the time the disease responds to a treatment without growth or spread).
We wanted to see if adding a (proteasome inhibitor) thats easier to take, which is a once-a-week pill, or (else) patients will have to come into the hospital, etc., will be safe, No. 1, and it wont cause more toxicity, but No. 2, is there a signal that this could actually be better than (Revlimid) maintenance, Patel said.
In 39 patients, rates of response to maintenance therapy deepened over time. In particular, 43% of patients achieved a complete response (disappearance of all signs of cancer from treatment, although it does not denote a cure to the disease), and a median overall survival was not reached during a median follow-up of 62 months. Of note, when median overall survival is not reached, this means that at least half of patients in the study were alive at the time researchers assessed this factor.
Median progression-free survival in all patients in the study was 73 months and had not been reached in patients with stage 1 disease. The nine patients with stage 3 disease had a median progression-free survival of 34 months, and the 14 patients with high-risk disease had a median progression-free survival of 25 months.
The high-risk patients, which is where we were hoping it would have the most benefit unfortunately, we didn't have very many high-risk patients on the study, Patel said. High-risk patients still need better options (for maintenance therapy) out there.
Progressive disease was observed in 22 patients, and 19 patients continued to receive maintenance therapy with this two-medication approach.
The most common severe or life-threatening side effects that occurred throughout the study included leukopenia (low white blood cell count), neutropenia (low counts of neutrophils, a type of white blood cell), lung infections, thrombocytopenia (low blood platelet count), maculopapular rash (a rash with flat and raised areas) and diarrhea. Nine patients developed second primary malignancy.
Toxicity led to a Ninlaro dose reduction in 20 patients and a Revlimid dose reduction in 31 patients. Four patients discontinued Ninlaro because of toxicity.
Mild or moderate neuropathy (weakness, pain and numbness from nerve damage in the hands and feet) was observed in 22 patients and led to a dose reduction or discontinuation of Ninlaro in two patients.
Phenomenal Safety and Ease With Combination Maintenance
Most of these patients actually did well with both drugs, Patel said. The toxicities, we actually saw less neuropathy than you would with bortezomib (Velcade), for instance, which a lot of people do use in combination with (Revlimid) for maintenance, especially high-risk patients. The safety and the ease were pretty phenomenal for most of these patients.
There are several limitations to this study including the fact that it had 64 patients, making it a smaller study, and that most patients had standard risk compared with a higher risk.
To be tolerated well and to be able to get this great (progression-free survival), of course, we need randomized trials to really prove that (progression-free survival) is significantly better than (Revlimid) maintenance alone, Patel said. I do think that there are patients that really would benefit (from this maintenance approach).
For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.
Go here to read the rest:
- Unparalleled Research on Adipose Tissue-Derived Stem Cell Therapy Market With Current and Future Growth ... - openPR - May 15th, 2024
- 100 plus years of stem cell research20 years of ISSCR - PMC - March 26th, 2024
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 18th, 2024
- Stem cell research project to launch into space - Fox Weather - January 24th, 2024
- Breakthrough in cancer research opening up stem cell therapy to more people. How you can get involved - 69News WFMZ-TV - January 20th, 2024
- Stem Cell Research Heading to the ISS on Axiom Mission 3 - ISS National Lab - January 18th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - The Dispatch - January 12th, 2024
- Applications are open for the Maryland Stem Cell Research Fund - Technical.ly - January 4th, 2024
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by 2031: Says Allied Market Research - Yahoo Finance - November 19th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance Regenrative Medicine - Yahoo Finance - November 3rd, 2023
- Research Fellow (Aging and Cancer Stem Cell Laboratory ... - Times Higher Education - October 15th, 2023
- Qkine Collaborates with the Cambridge Stem Cell Institute to Facilitate Same-Day Access to Key Research Products for Researchers at the Cambridge... - September 27th, 2023
- Stem cells: a comprehensive review of origins and emerging clinical ... - September 25th, 2023
- Stem Cell Research and Communicating Science | GBH - GBH News - September 20th, 2023
- Stem cell research reveals the earliest stages of a human life - SBS News - September 10th, 2023
- Stem Cell Therapy Market Size 2023 | Innovative Research Methodologies with Emerging Trends and Opportuni - Benzinga - September 10th, 2023
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research, Current Trends, Key Industry Play - Benzinga - September 8th, 2023
- Stem Cell Therapy Market 2023 Business Statistics and Research ... - The Knox Student - August 28th, 2023
- Autologous Stem Cell Based Therapies Market Analysis, Research ... - Chatfield News-Record - July 19th, 2023
- Global Stem Cell Market Projected to Reach $14 Bn by 2028: Ken Research - Yahoo Finance - July 11th, 2023
- Theradaptive Awarded Manufacturing Assistance Grant by the Maryland Stem Cell Research Fund - Benzinga - July 10th, 2023
- Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual... - June 19th, 2023
- Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023... - June 17th, 2023
- Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments - Yahoo... - June 17th, 2023
- Lung and heart stem cell research paves way for new COVID-19 treatments - Medical Xpress - June 14th, 2023
- Toxicology PhD student cultivating giant leaps in stem cell research ... - June 4th, 2023
- Harvard Stem Cell Institute (HSCI) - May 26th, 2023
- Findings may lead to improved insulin-secreting cells derived from stem ... - May 26th, 2023
- Cell Press: Stem Cell Reports - May 26th, 2023
- Stem cell research could enable blood to be made in other parts of the body - Medical Xpress - May 26th, 2023
- Construction of myocardial patch with mesenchymal stem cells and poly ... - May 22nd, 2023
- Cedars-Sinai to Send Stem Cells to the Space Station to Aid in the ... - May 22nd, 2023
- researchers expand human blood stem cells | Institute for Stem Cell ... - May 22nd, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Exclusive Research Report on Msenchymal Stem Cell and Exosome Diagnostics and Therapies Market to Witness Comp - openPR - May 17th, 2023
- The Future of Stem Cell Research: Master of Science in ... - The Daily | Case Western Reserve University - May 10th, 2023
- Exclusive Research Report on Stem Cell Therapy for Diabetes and ... - Digital Journal - May 9th, 2023
- Aging melanocyte stem cells and gray hair | National Institutes of ... - May 5th, 2023
- Mouse hair turns gray when certain stem cells get stuck - May 5th, 2023
- Science-First Skincare Company Michal Morrison Secures Exclusive World-Wide License of Proprietary STEM6 Molecule, Supported by Over 25 Years of... - May 5th, 2023
- BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansi - Benzinga - May 3rd, 2023
- Hair turning gray? Study finds a stem cell 'glitch' may be the cause - May 1st, 2023
- Elevai Labs Announces Research Grant Award and Partnership to Better Characterize the 'Payload' of ELEVAI's Stem Cell-derived Exosomes - Yahoo Finance - April 27th, 2023
- Why does hair turn gray? A new study says 'stuck' stem cells may ... - NPR - April 27th, 2023
- Study advances understanding of how melanocyte stem cells work to color ... - April 21st, 2023
- Stem cell research and therapy legislation to be replaced, says ... - Bahamas Tribune - April 21st, 2023
- Stem Cell Research (journal) - Wikipedia - April 21st, 2023
- Scientists Are About to Try to Create Stem Cells in Space - April 21st, 2023
- Stem Cell Research & Therapy | Articles - BioMed Central - April 16th, 2023
- Stem Cell Junk Yards Reveal a New Clue About Aging | WIRED - April 16th, 2023
- Global Stem Cells Market Research Report 2023: Implications - April 16th, 2023
- Stem cell research can help people with hard- | EurekAlert! - April 16th, 2023
- University Of Edinburgh's stem cell research gets funding boost - India Education Diary - April 14th, 2023
- Two major stem cell research projects supported with more than ... - University of California, Santa Cruz - April 8th, 2023
- Cancer detection predicts tumors before they form: discovery - March 29th, 2023
- Stem cell therapy: a potential cure for hearing loss? - March 29th, 2023
- Turkey's Only Stem Cell Production Application and Research Center - Expat Guide Turkey - March 24th, 2023
- Stem Cell Research Article, Embryonic Cells Information, Cell Therapy ... - March 24th, 2023
- Scientists create mice with cells from 2 males for 1st time - March 19th, 2023
- QBRI concludes stem cells symposium - Gulf Times - March 17th, 2023
- 2020 California Proposition 14 - Wikipedia - March 17th, 2023
- Stem Cell Reports | Journal | ScienceDirect.com by Elsevier - March 17th, 2023
- Stem cell therapy MSC-NP found to ease inflammatory activity of brain ... - March 12th, 2023
- Stem Cell Research | Office of Research Compliance | SIU - March 12th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Stem cells drive antler regeneration | Science - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Stem Cell Research | Thermo Fisher Scientific - US - March 4th, 2023
- Stem cell controversy - Wikipedia - February 28th, 2023
- National Institutes of Health grant funds interdisciplinary ... - February 27th, 2023
- Research Associate in Cancer Stem Cell Research job with ... - Times Higher Education - February 25th, 2023
- Pioneering Stem Cell Research Conference at The Aga Khan ... - The Aga Khan University - February 25th, 2023
- Scientists grapple with ethics of stem cell research - STAT - February 17th, 2023
- Research Associate in Stem Cell Neurobiology job with KINGS ... - Times Higher Education - January 30th, 2023
- Stem cells: past, present, and future | Stem Cell Research & Therapy ... - January 12th, 2023
- Edu Thesis & Essay: Stem cell research outline top writers online! - January 12th, 2023
- Stem Cell Biology Research Program | Johns Hopkins Institute for Cell ... - January 5th, 2023
- Stem cell population identified is vital for bone regeneration: Research - ThePrint - January 5th, 2023
- Leading scientist 'blown away' by UAE advances in stem cell research - The National - December 15th, 2022
Recent Comments